{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:19:31Z","timestamp":1776125971851,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"General Program of Huai\u2019an natural science fund projects","award":["HAB 202045"],"award-info":[{"award-number":["HAB 202045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately 60% of patients with autoimmune encephalitis (AE) exhibit secondary acute symptomatic seizures and showed highly sensitive to immunotherapy. However, it is difficult for many patients to receive early immunotherapy since the early identification of the cause in AE is more complex. This study aimed to investigate the early predictors of initial immune-related seizures and to guide the evaluation of treatment and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred and fifty-four patients with new-onset \u201cunknown etiology\u201d seizures with a course of disease less than 6 months were included. Serum and\/or cerebrospinal fluid neuron-specific autoantibodies (NSAbs), including N-methyl-D-aspartate receptor (NMDAR), \u03b1-amino-3-hydroxy-5- Methyl-4-isoxazole propionic acid receptor 1 (AMPAR1), AMPAR2, anti-leucine rich glioma inactivated 1 antibody (LGI1), anti-gamma-aminobutyric acid type B receptor (GABABR), anti-contact protein-related protein-2 (CASPR2) were used to screen for immune etiology of the seizures. In addition, patients with epilepsy and encephalopathy were also examined via brain MRI, long-term video EEG, antibody prevalence in epilepsy and encephalopathy (APE2) score, and modified Rankin Scale (mRS). A logistic regression model was used to analyze the early predictors of immune etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four cases (22.1%) were positive for NSAbs. Among all 154 patients, 23 cases of autoimmune encephalitis (AE) (21 cases of NSAbs positive), 1 case of ganglionic glioma (NSAbs positive), 130 cases of epilepsy or seizures (12 cases of NSAbs positive) were recorded. Also, there were 17 patients (11.0%) with APE2\u2009\u2265\u20094 points, and all of them met the clinical diagnosis of AE. The sensitivity and specificity of APE2\u2009\u2265\u20094 points for predicting AE were 73.9% and 100%. The results of multivariate analysis showed that the NSAbs and APE2 scores independently influenced the early prediction of initial immune-related seizures (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NSAbs and APE2 scores could act as early predictors of initial immune-related seizures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-03042-0","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:03:03Z","timestamp":1672272183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early predictors of new-onset immune-related seizures: a preliminary study"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiangsong","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiulin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengbing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"3","key":"3042_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","volume":"88","author":"KM Fiest","year":"2017","unstructured":"Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296\u2013303.","journal-title":"Neurology"},{"issue":"2","key":"3042_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ene.15141","volume":"29","author":"JOT Sipil\u00e4","year":"2022","unstructured":"Sipil\u00e4 JOT, K\u00e4lvi\u00e4inen R. Adult onset epilepsy incidence in Finland over 34 years: a nationwide registry study. Eur J Neurol. 2022;29(2):605\u20138.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3042_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD 2016 Epilepsy Collaborators","year":"2019","unstructured":"GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3042_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671\u20135.","journal-title":"Epilepsia"},{"issue":"4","key":"3042_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for classification and terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia"},{"issue":"9","key":"3042_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"3042_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391\u2013404.","journal-title":"Lancet Neurol"},{"issue":"3","key":"3042_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/JCI125178","volume":"129","author":"C Geis","year":"2019","unstructured":"Geis C, Planagum\u00e0 J, Carre\u00f1o M, et al. Autoimmune seizures and epilepsy. J Clin Investigat. 2019;129(3):926\u201340.","journal-title":"J Clin Investigat"},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/brain\/awq113","volume":"133","author":"SR Irani","year":"2010","unstructured":"Irani SR, Bera K, Waters P. Et a1. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655\u201367.","journal-title":"Brain"},{"issue":"4","key":"3042_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u201382.","journal-title":"Epilepsia"},{"issue":"2","key":"3042_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/epi.14649","volume":"60","author":"D Dubey","year":"2019","unstructured":"Dubey D, Pittock SJ, McKeon A. Antibody prevalence in Epilepsy and Encephalopathy score: increased specificity and applicability. Epilepsia. 2019;60(2):367\u20139.","journal-title":"Epilepsia"},{"issue":"3","key":"3042_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","volume":"16","author":"KS Husari","year":"2019","unstructured":"Husari KS, Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019;16(3):685\u2013702.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"3042_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/jnnp-2020-325011","volume":"92","author":"RN McGinty","year":"2021","unstructured":"McGinty RN, Handel A, Moloney T, et al. Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. J Neurol Neurosurg Psychiatry. 2021;92(3):291\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"3042_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/epi.13797","volume":"58","author":"D Dubey","year":"2017","unstructured":"Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58(7):1181\u20139.","journal-title":"Epilepsia"},{"issue":"6","key":"3042_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/epi.12127","volume":"54","author":"T Brenner","year":"2013","unstructured":"Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54(6):1028\u201335.","journal-title":"Epilepsia"},{"issue":"4","key":"3042_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","volume":"74","author":"D Dubey","year":"2017","unstructured":"Dubey D, Alqallaf A, Hays R, et al. Neurological Autoantibody Prevalence in Epilepsy of unknown etiology. JAMA Neurol. 2017;74(4):397\u2013402.","journal-title":"JAMA Neurol"},{"issue":"7","key":"3042_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/epi.16571","volume":"61","author":"C Steriade","year":"2020","unstructured":"Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definition. Epilepsia. 2020;61(7):1341\u201351.","journal-title":"Epilepsia"},{"issue":"11","key":"3042_CR18","doi-asserted-by":"publisher","first-page":"e01442","DOI":"10.1002\/brb3.1442","volume":"9","author":"J Zelano","year":"2019","unstructured":"Zelano J, Axelsson M, Constantinescu R, et al. Neuronal antibodies in adult patients with new-onset seizures: a prospective study. Brain Behav. 2019;9(11):e01442.","journal-title":"Brain Behav"},{"issue":"5","key":"3042_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ana.22307","volume":"69","author":"SR Irani","year":"2011","unstructured":"Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892\u2013900.","journal-title":"Ann Neurol"},{"issue":"1","key":"3042_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ana.22470","volume":"70","author":"P Striano","year":"2011","unstructured":"Striano P. Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol. 2011;70(1):179\u201380.","journal-title":"Ann Neurol"},{"issue":"2","key":"3042_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","volume":"13","author":"N Gresa-Arribas","year":"2014","unstructured":"Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167\u201377.","journal-title":"Lancet Neurol"},{"issue":"9","key":"3042_CR22","first-page":"1095","volume":"39","author":"Y Ni","year":"2019","unstructured":"Ni Y, Chen S. Advances of pathogenesis and clinical research in anti-N-methyl-D-aspartate receptor encephalitis. J Shanghai Jiao Tong Univ (Medical Science). 2019;39(9):1095\u20139.","journal-title":"J Shanghai Jiao Tong Univ (Medical Science)"},{"issue":"4","key":"3042_CR23","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s10072-021-05617-0","volume":"43","author":"H Elkhider","year":"2022","unstructured":"Elkhider H, Sharma R, Kapoor N, et al. Autoimmune encephalitis and seizures, cerebrospinal fluid, imaging, and EEG findings: a case series. Neurol Sci. 2022;43(4):2669\u201380.","journal-title":"Neurol Sci"},{"key":"3042_CR24","doi-asserted-by":"publisher","first-page":"6666117","DOI":"10.1155\/2021\/6666117","volume":"2021","author":"B Douma","year":"2021","unstructured":"Douma B, Ben Younes T, Benrhouma H,et al. Autoimmune encephalitis in Tunisia: report of a Pediatric Cohort. J Immunol Res. 2021;2021:6666117.","journal-title":"J Immunol Res"},{"issue":"3","key":"3042_CR25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/epi.16820","volume":"62","author":"Y Li","year":"2021","unstructured":"Li Y, Tymchuk S, Barry J, et al. Antibody prevalence in Epilepsy before surgery (APES) in drug-resistant focal epilepsy. Epilepsia. 2021;62(3):720\u20138.","journal-title":"Epilepsia"},{"issue":"7","key":"3042_CR26","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/epi.17245","volume":"63","author":"X Liu","year":"2022","unstructured":"Liu X, Guo K, Lin J, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: a prospective observational registry study update. Epilepsia. 2022;63(7):1812\u201321.","journal-title":"Epilepsia"},{"issue":"2","key":"3042_CR27","first-page":"91","volume":"50","author":"Neurology Branch of Chinese Medical Association","year":"2017","unstructured":"Neurology Branch of Chinese Medical Association. Expert consensus on the diagnosis and treatment of chinese autoimmune encephalitis. Chin J Neurol. 2017;50(2):91\u20138.","journal-title":"Chin J Neurol"},{"issue":"3","key":"3042_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/jnnp-2020-325350","volume":"92","author":"S R\u00fcegg","year":"2021","unstructured":"R\u00fcegg S. Antineuronal antibodies and epilepsy: treat the patient, not the lab. J Neurol Neurosurg Psychiatry. 2021;92(3):230.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03042-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03042-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03042-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:03:26Z","timestamp":1672272206000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03042-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03042-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2043785\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the ethical standards of the declaration of Helsinki. The study protocol was approved by the research ethics committee of Huai\u2019an Third People\u2019s Hospital (No.2016-008). We obtained informed written consent from all subjects and their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"503"}}